Objective. The purpose of this study was to assess the feasibility of using a contrast agent for the sonographic examination of adnexal tumors and identify discriminating parameters in the preoperative diagnosis of malignant tumors. Methods. We conducted a prospective descriptive monocenter study that analyzed validated echographic criteria and parameters of the enhancement curve obtained by sonographic contrast agent injection. Patients included were referred for a second opinion after the discovery of a suspicious ovarian image. The final diagnosis was reached after surgery and an anatomopathologic examination. Results. Fifty-two tumors were analyzed. Morphologic and Doppler criteria analyses were conducted as described in the literature. The significant parameters of the enhancement curve were the time-intensity curve total area and the duration of activity of the contrast agent during the first phase of decay (P < .002). The performance of the contrast agent was lower than that of the examiner's subjective diagnosis, with an area under the receiver operating characteristic curve (AUC) of 0.78 versus 0.80. When borderline tumors were eliminated, there was an inversion of this, with an AUC of 0.85 versus 0.73. The inclusion of contrast results in the examiner's diagnosis in the context of a bivariate model comparing malignant and borderline tumors with benign tumors provided an AUC of 0.88. Conclusions. Contrast-enhanced sonography improves preoperative diagnosis of ovarian tumors parameters. The significant parameters of the enhancement curve were significantly different for malignant and benign tumors. Borderline tumors contribute to a reduction of the discriminating capacity of the contrast agent. Key words: contrast-enhanced sonography; borderline tumor; ovarian tumor; SonoVue; tumor vascularization. Abbreviations ACA 1, activity of the contrast agent in phase 1; AUC, area under the receiver operating characteristic curve; CA-125, cancer antigen 125; NPV, negative predictive value; PI, pulsatility index; PPV, positive predictive value; RI, resistive index; ROC, receiver operating characteristic; TIC, time-intensity curve he prevalence of ovarian cancer is about 24,000 new cases every year in the United States. Even though relatively rare, it is nevertheless the third leading cause of mortality from female genital cancer. Its prognosis remains poor because in most cases the diagnosis is reached at late stages of the disease: it is generally established at advanced stages (III and IV) in 60% to 80% of cases, with a 5-year survival rate of lower than 25%. On the contrary, patients with a diagnosis of a stage I tumor can hope for 5-year survival of 80% to 95%.
he prevalence of ovarian cancer is about 24,000 new cases every year in the United States. Even though relatively rare, it is nevertheless the third leading cause of mortality from female genital cancer. Its prognosis remains poor because in most cases the diagnosis is reached at late stages of the disease: it is generally established at advanced stages (III and IV) in 60% to 80% of cases, with a 5-year survival rate of lower than 25%. On the contrary, patients with a diagnosis of a stage I tumor can hope for 5-year survival of 80% to 95%. 1, 2 Endovaginal pelvic sonography is the reference examination for investigating diseases of the uterus and its adnexa. The specificity of the technique for ovarian diseases has been determined to be 75% to 80%, with sensitivity of 80% to 85%, enabling a malignant lesion to be suspected but without being able to confirm or invalidate the diagnosis. This preoperative characterization of the diagnosis is currently an important clinical concern.
Considerable experimental work has been devoted to studying tumor neoangiogenesis, responsible for specific vascular modifications 3 ; it can be only partially evaluated by pulsed Doppler and power Doppler imaging. The characteristics of this neovascularization are now accessible via new methods of computer-assisted sonographic imaging: vascular quantification and study of the enhancement curve versus time, or time-intensity curve (TIC). Quantifying the digitized vascular index does not appear to improve the preoperative diagnosis despite initially promising results. 4 Pelvic sonography with injection of a contrast agent overcomes these difficulties by increasing the effectiveness of investigating tumor vascularization and enabling vascular enhancement to be studied in real time. 5 This work was undertaken to analyze (1) morphologic and Doppler sonographic criteria validated in the literature and (2) TICs and their parameters with respect to the anatomopathologic status of the tumor to determine the feasibility of this technique for preoperative analysis of ovarian lesions.
Materials and Methods
This prospective descriptive monocenter study compared morphologic and Doppler echographic criteria and TIC parameters of ovarian lesions with the final diagnosis. Included patients were referred to the imaging group of the Centre Hospitalier Universitaire de Tours for a second opinion before surgery after the discovery of a suspicious ovarian image. Objectively benign tumors were not included. The examination involved "conventional" pelvic sonography with a Technos MTX system (Esaote SpA, Rome, Italy) equipped with a 9-5 MHz probe, followed by recording a video sequence after injection of SonoVue (Bracco SpA, Milan, Italy), a sulfur hexafluoride microbubble contrast agent.
Inclusion criteria were patients aged 18 years or older presenting a suspicious or complex adnexal mass shown by sonography and scheduled for surgery, regardless of the type of mass. Exclusion criteria were as follows: typical isolated liquid unilocular, dermoid, and endometrial cysts; typical ovarian neoplasia, stages IIIc and IV; a contraindication to surgery, obviating an accurate histologic diagnosis; patients with known cardiopathy or coronary artery disease; patients who received another contrast agent within 24 hours preceding the SonoVue examination; patients who participated in another drug product clinical study within the preceding 30 days; and pregnant or breast-feeding patients.
The definitive diagnosis was obtained by an anatomopathologic examination of a surgical specimen. This work was approved by the Ethics Committee/Institutional Review Board, and all patients furnished written informed consent.
The first step involved classic endovaginal pelvic sonography that could be extended by abdominal sonography if the lesion was extensive. Morphologic criteria involved 3 parameters: density (liquid, solid, or mixed), the presence of septa (>3 or <3 mm) and vegetations. Power Doppler imaging with a 500-Hz radio frequency pulse enabled vascular mapping of the lesion. The pulsatility index (PI) and resistive index (RI) were calculated. Several measurements were made, and only the lowest values were used.
The second step involved endovaginal contrastenhanced sonography. The examiner initially selected a slice of the ovary representative of the lesion and held the probe in position for the entire duration of the recording. A 4.8-mL bolus of SonoVue was injected into an antebrachial vein. Time 0 was the moment the bolus was injected. This was immediately followed by injecting 5 mL of saline solution via the catheter. The recording involved a 5-minute video sequence starting at time 0. The video file was stored on the hard disk of the machine for analysis at a later time. All images were taken by the same examiner, who at the end of each examination gave his opinion of the malignant, benign, or borderline nature of the lesion examined, based only on morphologic and Doppler criteria. The video sequences were analyzed blind by a second examiner who did not know the definitive histologic results.
A region of interest was determined for each video sequence, defined as the most suspicious or most representative of the plane of section chosen. This region of interest was the zone containing the most vascularization and solid components. In the case of a pure unilocular cyst, the region selected was the cyst wall or ovarian parenchyma closest to the cyst. Time Intensity Analysis 7.1 software (Esaote) was used to obtain the TIC expressing the Doppler intensity (decibels) versus time (seconds) in the zone selected. The maximal intensity was first determined, followed by analysis of other parameters of the curve after applying smoothing and normalization functions (value of maximal intensity set at 1 dB).
Modeling wash-out kinetics of a contrast agent reveals two different components with different slopes: an initial phase (phase 1) with rapid decay, followed by a phase of slow decay (phase 2). Phase 1 is the first pass of the contrast agent in arterial circulation; phase 2 is partly explicable by elimination of the product, explaining its longer duration. 6 The TIC was used to determine several parameters (Figure 1 ): the time for the product to arrive in the tumor (seconds), maximal intensity (decibels) and time taken to reach it (seconds), TIC total area (decibels × seconds), halfwash-out time (seconds) that determines slopes 1 and 2, and duration of the activity of the contrast agent in phase 1 (ACA 1, seconds), defined by the intersection of slope 1 with the baseline.
Statistical analysis was conducted with SPSS 16.0 (SPSS Inc, Chicago, IL) and SAS 9.1 (SAS Institute Inc, Cary, NC) software. The χ 2 test was used to assess the distribution of benign and malignant tumors according to qualitative variables (morphologic criteria). An analysis of variance was used to determine intergroup variances between benign, borderline, and malignant tumors according to quantitative variables (RI, PI, cancer antigen 125 [CA-125], and TIC parameters). Parameters with a significant difference were analyzed by plotting a receiver operating characteristic (ROC) curve, measuring the area under the ROC curve (AUC) to determine their capacity to discriminate between benign and malignant tumors. Finally, a bivariate model was constructed to evaluate the contribution of the contrast agent to the strategy of preoperative echographic diagnosis of ovarian tumors.
Results
Among the 64 patients included between May 2005 and May 2008, 55 TICs could be analyzed. Among them, 52 were usable: 1 patient was lost from sight, and surgery was contraindicated for 2 patients because of a poor general state. The 9 unusable TICs resulted from artifacts during recording of the video sequence. Among the 52 patients analyzed, ovarian lesions were malignant in 23% of cases (n = 12), borderline in 20% (n = 10), and benign in 57% (n = 30; Table 1 ). In the group of malignant tumors, the mean age was 50.6 years (range, 34-68 years), and in the group of benign tumors, it was 49.3 years (range, 20-80 years).
The univariate analysis showed a significant difference when intracyst vegetations were present (P < .001) and when a solid tumor component was present (P < .026). Intergroup variance was significant for the RI (P < .001), whereas for Figure 1 . Principal parameters of the enhancement curve obtained by contrast-enhanced sonography after smoothing and normalization. 1, Time for product arrival; 2, time to obtain the intensity peak; 3, maximal intensity; 4, half-wash-out point; 5, wash-out; area 1, area under slope 1; and total area, area 1 + area 2. the PI, the trend was nonsignificant; quantification of CA-125 was statistically nonsignificant (Table 2) . Receiver operating characteristic curves were prepared to assess the discriminating capacity of these validated criteria in our population. The echographic diagnosis (subjective) by the examiner using morphologic and Doppler criteria was based on an AUC of 0.795, sensitivity of 86%, specificity of 73%, a positive predictive value (PPV) of 70%, and a negative predictive value (NPV) of 88%. When borderline tumors were excluded from the population of malignant tumors, the AUC became 0.725, sensitivity 75%, and specificity 73%. The RI yield remained stable in both cases, with an AUC of 0.763 versus 0.728, sensitivity of 77% versus 75%, and specificity of 77 versus 77%. After injection of SonoVue, the intensity of the signal and vascularization both increased subjectively in 94% of the cases (n = 49). Three tumors found to be benign showed pseudovegetations/septa not enhanced by the contrast agent, interpreted as related to deposits/clots inside the cysts. A TIC with an early peak and a relatively rapid decay was found in all cases. Return of the sequence to the baseline within 5 minutes was seen in only 58% of the cases (n = 30). This result was expected in light of the longer persistence of SonoVue in the body, explaining why phase 2 parameters were not used as variables.
Time-intensity curve analysis revealed no significant difference for the time of product arrival, maximal intensity, and slope determined by the half-wash-out time (slope 1). The total area under the TIC as well as the area of phase 1 according to slope 1 (area 1) revealed a significant increase (P < .002) consistent with the histologic status (Table 3 ). The total area of malignant tumors was significantly larger than that of borderline tumors and benign tumors: 164, 147, and 123 dB × seconds, respectively (Figures 2 and 3) . The ACA 1 determined by the half-wash-out time increased significantly (P < .006) for malignant tumors; it was 120.3 seconds for benign tumors, Receiver operating characteristic curves were prepared to determine the discriminating capacities of TIC parameters (Tables 4 and 5 ). When borderline tumors were included in the group of malignant tumors, the AUC of the TIC total area was 0.775, with sensitivity of 68% and specificity of 83%. For the threshold of 152 dB × seconds, there were 5 false-positive and 7 false-negative results, 5 of which were borderline tumors. When borderline tumors were excluded from the analysis, the AUC for the same parameter was 0.846 with sensitivity of 83% and specificity of 87%. In this case, for the threshold of 159 dB × seconds, there were 4 false-positive and 2 false-negative results (Figure 4) . The statistical comparison test (method of DeLong et al 7 ) with AUC values for the other parameters examined (area 1 and ACA 1) revealed no significant difference, whether the entire population was considered (P = .779 for area 1; P = .33 for ACA 1) or by excluding borderline tumors (P = .35 for area 1; P = .217 for ACA 1). Because the AUC and performance of the TIC total area were consistently better indicators than other parameters, the total area was used as the most discriminating element of the TIC.
Contrast-Enhanced Sonography of Ovarian Tumors
A bivariate model was constructed to determine the contribution of contrast-enhanced sonography to clinical practice. Parameters of the TIC were added to a model already containing the tumor classification resulting from the examiner's diagnosis by comparing malignant and borderline tumors with benign tumors (Table 6 ). The purpose was to determine whether these parameters could provide additional information to the clinician's judgment. Performance of the echographic diagnosis (AUC of 0.795) increased by 8% for the TIC total area (our best parameter), giving the model an AUC of 0.875. This enabled 2 additional malignant tumors to be discriminated. No discriminating element in the analysis strategy was found between malignant and borderline tumors by using AUC values. . 8 The second factor is central vascularization of the tumor, reported to be one of the most specific criteria of malignancy. 9 The third is quantification of this vascularization with an objective criterion that has not been shown to provide better results than the examiner's subjective diagnosis. The most relevant Doppler sonographic parameter for differentiating benign from malignant tumors remains the subjective echographic diagnosis reached by a trainer examiner. No published mathematical model has yet replaced the effectiveness of this subjective evaluation, even in a subgroup of tumors qualified as "difficult to diagnose" 10 or for borderline tumors, 11, 12 whose diagnosis may be more difficult than for invasive and benign tumors. 13 In our experience, the univariate analysis also showed that the clinician's judgment is the most discriminating factor in the diagnosis of malignancy, with an AUC of 0.795, sensitivity of 86%, and specificity of 73%. These numbers are nevertheless lower than published data, for which there are two possible reasons. First, the goal of our work was not to establish the effectiveness of contrast-enhanced sonography for screening purposes but rather to determine its contribution in a subgroup of tumors that poses problems to the examiner. Our selection criteria thus aimed at eliminating unequivocally diagnosed benign and malignant tumors (explaining the high prevalence of malignant lesions in our population). It is to be noted that most published data are often provided by acknowledged experts in the field and thus only partially reflect the results of most sonographic examiners. Second, our inclusion criteria resulted in a particular sampling of malignant tumors, most of which were of a rare or unusual histologic type.
Sonographic imaging with SonoVue provides real-time low-index imaging, a benefit for the dynamic analysis of enhancement, particularly during the early phase. The late phase, on the other hand, is extended because of accumulation of the product in microvascularization of the parenchyma. 14, 15 In our experience, this increased elimination time resulted in a return to the baseline requiring more than 5 minutes in 42% of cases, explaining why parameters of the late phase were not considered in this work. The other result was a probable underestimation of the values of total areas of malignant tumors (a return to the baseline in <260 seconds was noted 
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for 63% of benign tumors versus 36% of malignant tumors). The kinetics of SonoVue involve a short lag time before the intensity peak, followed by a biphasic decay phase, consistent with data obtained in an animal model. These kinetics can be evaluated subjectively by determining the intensity of enhancement versus duration or objectively by quantifying TIC parameters. A region of interest not enhanced by the contrast agent or with a rapid return to the baseline intensity (subjective appreciation of the elimination time) suggests the diagnosis of a benign tumor. 16 Qualitative evaluation of microvascularization within papillary projections, however, does not increase discrimination between benign and borderline/malignant tumors because of the increased occurrence of false-positive results. 17 Among TIC parameters that can be measured, the TIC total area and ACA 1 were significantly higher for malignant tumors than for benign tumors: determination of their discriminating capacity revealed an AUC of 0.775 versus 0.698. These data do not replace the examiner's subjective diagnosis. On the other hand, using the parameters of the contrast agent improved the clinician's diagnostic performance compared with a univariate model, with respective AUC results of 0.875 versus 0.795.
There are relatively few publications dealing with contrast sonography of the ovary, but all report the same parameters to be significant. Thus, Ordén et al, 18 using Levovist (Schering AG, Berlin, Germany), reported activity of the contrast agent and the area under the slope during phases 1 and 2 as significant parameters. Their best parameter was the duration of activity of the contrast agent, established with a slope of 1, subjectively assessed visually, with sensitivity of 93% and specificity of 92%. 18 Marret et al 19 also using Levovist, reported the TIC total area and time of contrast wash-out as significant parameters. The best parameter was the TIC total area, with an AUC of 0.950, sensitivity of 96%, and specificity of 95%. 19 Fleischer et al [20] [21] [22] used Definity (Bristol-Myers Squibb Medical Imaging, North Billerica, MA) and reported the TIC total area, maximal intensity, and half-wash-out time as significant parameters. The best parameter was the TIC total area, with sensitivity of 100% and specificity of 96%. [20] [21] [22] It is to be noted that the population of borderline tumors in these studies was very low (2 of 32 in the work of Marret et al 19 ), null, or excluded from the statistical analysis.
Our results have validated the area under the enhancement curve as the contrast parameter to use because this parameter provided the best Veyer et al The prevalence of malignant tumors in the study population was 29%. NA indicates not applicable. The prevalence of malignant tumors in the study population was 42%. NA indicates not applicable.
results. Its discriminating capacity, however, is insufficient for replacing the subjective diagnosis of the examiner. We did not find the capacity of the contrast agent (concordance >92%) in our series, probably explained by the large population of borderline tumors, responsible for the overlap of our populations of invasive and benign tumors. The performance of contrastenhanced sonography is higher for distinguishing invasive from noninvasive tumors, except for borderline tumors. In our population, the latter accounted for 46% of malignant tumors. When borderline tumors were excluded from the group of malignant tumors, the performance of the contrast agent parameters exceeded those of the examiner's diagnosis. In this case, the AUC of the total area was 0.846, and that of the echographic diagnosis was 0.725. Reduced performance of the examiner is explained by the fact that he was confronted with difficulties posed by certain malignant tumors, while his diagnosis of malignancy was 100% for highly suggestive borderline tumors with typical intracyst vegetations or the presence of a solid zone in a very large, slowly advancing liquid cyst. The angiogenesis of these tumors is probably very different from that of other malignant tumors. An international multicenter trial by Testa et al, 23 which analyzed the TIC of 72 solid ovarian tumors (of which 9 were borderline tumors) using SonoVue, validated the same parameters of the AUC and time of the presence of the contrast agent as our study to discriminate invasive and noninvasive tumors. This study also showed that the wash-out kinetics of borderline tumors were close to those of noninvasive tumors. 23 We used another approach, involving the AUCs of TIC parameters in a strategy for analyzing malignant versus borderline tumors. It was found that the contrast agent provided no element for discriminating between these two groups.
Borderline tumors were the source of falsenegative results in our prior work on digitized vascular quantification of ovarian tumors. The diagnostic effectiveness of the examiner using morphologic and Doppler criteria, however, is highly dependent on experience. 
